Inflammatory bowel disease (IBD) represents a group of multifactorial illnesses with increasing incidence worldwide. Crohn's disease (CD) and ulcerative colitis (UC) are the two most thoroughly defined phenotypes of IBD. IBD associated with primary sclerosing cholangitis (PSC) - a progressive biliary disease leading to cirrhosis and liver failure - is considered as specific IBD phenotype (also referred to as 'PSC - IBD') due to its clinical and pathophysiological characteristics. The aim of the experimental part of this thesis was to define specific features of PSC - IBD in the key areas of IBD pathogenesis. These are: microbiota composition, gut - barrier failure, genetic predisposition and aberrant cellular and antibody immune response. Furthermore, the other goals were to describe relation of IBD status and activity to liver transplantation (LTx) and carcinogenesis based on thorough analysis of clinical data in patients under surveillance at the liver transplantation unit. Using the next-generation parallel sequencing technology, we discovered specific bacterial and mycobial features of gut microbiota composition in PSC - IBD which significantly differed from UC and healthy controls recruited from Czech general population. Moreover, we identified numerous seral biomarkers distinguishing CD, UC...

Objectifs : La maladie de Crohn (MC) et la colite ulcéreuse (CU) sont associées à un fardeau socio-économique important. Au Canada, les analyses de coûts-utilité (ACU) sont privilégiées afin d’assurer l’allocation optimale des ressources. La mesure d’utilité est essentielle pour réaliser une ACU. L’objectif de ce projet visait à identifier les mesures d’utilité et d’estimer l’impact de ces mesures sur le ratio coût-utilité incrémental (RCUI) des traitements indiqués pour la MC. Méthodes : Un arbre décisionnel a été développé pour mesurer l’impact des valeurs d’utilité du EQ-5D, de l’échelle visuelle analogue (VAS), de l’arbitrage temporel (TTO) et du pari standard (SG), sur le RCUI d’Infliximab (IFX) + Traitements standards (TS) (prednisone, mesalazine (MZ), azathioprine (AZA), 6-mercaptopurine (6-MP)) vs Placébo + TS. Le modèle a porté sur un horizon temporel d’un an, selon les perspectives du système de soins et sociétale. Les moyennes pondérées des mesures d’utilité ont été estimées à partir d’une revue systématique de la littérature. Des analyses de sensibilités déterministes et probabilistes ont également été effectuées. Résultats : L’ensemble des RCUIs, variaient entre 67 068 $/QALY (TTO) et 268 385 $/QALY (EQ-5D). À un seuil de propension à payer de 50 000 $/QALY, la probabilité qu’IFX + TS soit coût efficace était nulle pour l’ensemble des analyses, à l’exception de celle du TTO (4,0%). Conclusion : La variabilité des mesures d’utilité a un impact considérable sur les RCUIs et nécessite une attention particulière de la part des preneurs de décisions, plus précisément au niveau des analyses de sensibilité. / Objectives: Crohn’s disease (CD) and ulcerative colitis are both associated with a high socioeconomic burden. In Canada, cost-utility analyses (CUA) are privileged in order to allocate healthcare spending efficiently. Since utility measures are essential for CUA, the objective of this study was to assess the impact utility values on the incremental cost-utility ratio (ICUR) of CD treatments. Methods: A decision-tree model was developed to assess the impact of utility values derived from the EQ-5D, the visual analogue scale (VAS), the time trade off (TTO) and the standard gamble (SG), on the resulted ICUR of Infliximab (IFX) + Standard of Care (SoC) (prednisone, mesalazine (MZ), azathioprine (AZA), 6-mercaptopurine (6-MP)) versus Placebo (Pbo) + SoC. The model was conducted over a one-year time horizon from the Canadian healthcare and societal perspectives. The weighted averages of utility values were estimated based on a systematic literature evaluation. Both deterministic and probabilistic sensitivity analyses were also conducted. Results: The ICURs ranged from $67,068/QALY (TTO) to $268,385/QALY (EQ-5D). At a $50,000/QALY threshold, the probability of IFX + SoC of being cost-effective was of 0% in most analyses except for the TTO method (4.0%). Conclusion: The variability of utility measures has a considerable impact on the ICURs and requires a special attention from decision-makers, in regards of sensitivity analyses.

No description available.

IN ENGLISH Drug dependency in inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC), is a specific disease phenotype which determines disease prognosis and hence may be used as a prognostic marker for treatment management. Drug dependency in IBD has been well described in corticosteroid treatment and recently also in infliximab (IFX) therapy. The aims of this thesis were: 1) to assess the occurrence of IFX dependency in paediatric and adult patients with CD; further to search for clinical and genetic predictors of IFX outcome and to evaluate the impact of IFX dependency on surgical rate; 2) to assess in CD patients the outcome of the first course of 5-ASA monotherapy with emphasis on 5-ASA dependency and to define clinical predictors of 5-ASA treatment outcome. We found that 66% of children and 29% of adults with CD became IFX dependent. The high frequency in paediatrics is in agreement with previously published studies, while the finding in adult patients indicates a lower rate of IFX dependency in the only study to date. Perianal disease and no bowel surgery prior to IFX start were predicative of IFX dependency in paediatric patients. In adult cohort, 2 genetic variants LTA c.207 A>G and CASP9 c.93 C>T were associated with IFX outcome, whereas no relevant clinical...

Hintergrund: Angaben zu Inzidenz und Prävalenz von chronisch entzündlichen Darmerkrankungen (CED) bei Kindern und Jugendlichen in Deutschland fehlen bisher, die Daten des im Jahr 2000 gegründeten Sächsischen CED-Registers für Kinder und Jugendliche wurden bisher nicht veröffentlicht. Bei internen Diskussionen der Registerdaten zeigte sich stets eine nicht erklärbare abfallende altersspezifische Inzidenz der CED ab dem 15. Lebensjahr. Es wurde vermutet, dass einige ältere Jugendliche ausschließlich von Erwachsenengastroenterologen betreut wurden und bei einigen Adoleszenten eine längere diagnostische Latenz zur Diagnosestellung nach dem 18. Lebensjahr führte. Patienten und Methoden: Zur Prüfung der Thesen wurden alle gastroenterologisch tätigen Internisten in Leipzig aufgesucht und Patienten eingeschlossen, bei denen bis zum 26. Lebensjahr in den Jahren 2005-2009 eine CED endoskopisch neu diagnostiziert wurde. Die Auswertung des Sächsischen CED-Registers erfolgte hinsichtlich Inzidenz, Prävalenz, Geschlechterverteilung und diagnostischer Latenz im Zehnjahreszeitraum 2000-2009. Ergebnisse: Es wurden tatsächlich einige Jugendliche vor dem 18. Lebensjahr ausschließlich von Internisten betreut und nicht an das Register gemeldet. Die korrigierte Inzidenz von CED bei Patienten bis zum 18. Lebensjahr in Leipzig lag um 37 % höher als im Register angegeben. Nach dem 15. Lebensjahr wurde – ebenfalls in Abweichung zu den Registerdaten – ein kontinuierlicher Anstieg der altersspezifischen Inzidenz bis zum 18. Lebensjahr registriert. Es zeigte sich eine Tendenz zur längeren diagnostischen Latenz bei Adoleszenten, die sich jedoch nicht statistisch sichern ließ. Bis zum 15. Lebensjahr wurden nahezu alle Patienten im CED-Register erfasst.:INHALTSVERZEICHNIS 1. EINLEITUNG 1.1 Definition chronisch entzündlicher Darmerkrankungen 1.1.1 Morbus Crohn 1.1.2 Colitis ulcerosa 1.1.3 Colitis indeterminata 1.1.4 Mikroskopische Kolitis 1.2 Ätiologie und Pathogenese 1.2.1 Genetik 1.2.2 Immunologie / Barrierestörung 1.2.3 Hygienehypothese 1.3 Klinische Symptome 1.4 Diagnostik 1.4.1 Anamnese und körperliche Untersuchung 1.4.2 Labordiagnostik 1.4.3 Bildgebung 1.4.4 Endoskopie 1.5 Therapie 2. AUFGABENSTELLUNG 3. PATIENTEN UND METHODEN 3.1 Sächsisches Register für Kinder und Jugendliche mit chronisch entzündlichen Darmerkrankungen 3.2 In Leipzig betreute Patienten mit CED bis zum 26. Lebensjahr 3.3 Sächsisches CED-Register und zweite Datenquelle Leipzig 3.3.1 Sächsisches CED-Register 3.3.2 Zweite Datenquelle Leipzig 3.3.3 Junge Patienten mit CED in Leipzig bis zum 26. Lebensjahr 3.3.4 Sächsisches CED-Register und junge Patienten mit CED in Leipzig bis zum 26. Lebensjahr 3.4 Software und statistische Analysen 4. ERGEBNISSE 4.1 Sächsisches CED-Register im Zeitraum 2000 bis 2009 4.1.1 Epidemiologie 4.1.1.1 Patienten 4.1.1.2 CED-Inzidenz bei Kindern und Jugendlichen in Sachsen im Zeitraum 2000 bis 2009 4.1.1.3 CED-Prävalenz bei Kindern und Jugendlichen in Sachsen im Zeitraum 2000 bis 2009 4.1.2 Alter bei Diagnosestellung der Kinder und Jugendlichen mit CED in Sachsen im Zeitraum 2000 bis 2009 4.1.3 Geschlecht der Kinder und Jugendlichen mit CED in Sachsen im Zeitraum 2000 bis 2009 4.1.4 Kinder und Jugendliche mit CED in Sachsen im Zeitraum 2000 bis 2009 – Lokalisation der Darmentzündung bei Diagnosestellung 4.1.4.1 Lokalisation der Darmentzündung bei Patienten mit CU zum Zeitpunkt der Diagnosestellung 4.1.4.2 Lokalisation der Darmentzündung bei Patienten mit MC zum Zeitpunkt der Diagnosestellung 4.1.5 Kinder und Jugendliche mit CED in Sachsen im Zeitraum 2000 bis 2009 – Diagnostische Latenz 4.1.5.1 Diagnostische Latenz in Abhängigkeit zu den Krankheitsgruppen 4.1.5.2 Diagnostische Latenz in Abhängigkeit zum Erkrankungsalter 4.1.5.3 Diagnostische Latenz und Lokalisation der Darmentzündung 4.2 In Leipzig betreute Patienten mit CED bis zum 26. Lebensjahr im Zeitraum 2005 bis 2009 4.2.1 Patienten 4.2.2 Alter bei Diagnosestellung der jungen Patienten mit CED in Leipzig im Zeitraum 2005 bis 2009 4.2.3 Geschlecht der jungen Patienten mit CED in Leipzig im Zeitraum 2005 bis 2009 4.2.4 Junge Patienten mit CED in Leipzig im Zeitraum 2005 bis 2009 – Lokalisation der Darmentzündung bei Diagnosestellung 4.2.4.1 Lokalisation der Darmentzündung bei Colitis ulcerosa-Patienten zum Zeitpunkt der Diagnosestellung 4.2.4.2 Lokalisation der Darmentzündung bei Morbus Crohn-Patienten zum Zeitpunkt der Diagnosestellung 4.2.5 Junge Patienten mit CED in Leipzig im Zeitraum 2005 bis 2009 – Diagnostische Latenz 4.2.5.1 Diagnostische Latenz in Abhängigkeit zu den Krankheitsgruppen 4.2.4.2 Diagnostische Latenz in Abhängigkeit zum Erkrankungsalter 4.2.5.3 Diagnostische Latenz und Lokalisation der Darmentzündung 4.3 Untersuchung junger Patienten mit CED in Leipzig im Zeitraum 2005 bis 2009 als mögliche zweite Datenquelle des Sächsischen CED-Registers für Kinder und Jugendliche 4.3.1 Altersstruktur der Leipziger Patienten mit CED, die im Zeitraum 2005 bis 2009 an das Sächsische CED-Register gemeldet wurden 4.3.2 Tatsächliche Altersstruktur der Leipziger Kinder und Jugendlichen sowie jungen Erwachsenen mit CED im Zeitraum 2005 bis 2009 nach Ergänzung durch die zweite Datenquelle 4.3.3 Tatsächliche Inzidenz der CED bei Kindern und Jugendlichen sowie jungen Erwachsenen in Leipzig im Zeitraum 2005 bis 2009 nach Ergänzung durch die zweite Datenquelle 5. DISKUSSION 6. ZUSAMMENFASSUNG 7. LITERATUR 8. ANHANG

The self-organizing maps portraying has been proven to be a powerful approach for analysis of transcriptomic, genomic, epigenetic, single-cell, and pathway-level data as well as for “multi-omic” integrative analyses. However, the SOM method has a major disadvantage: it requires the retraining of the entire dataset once a new sample is added, which can be resource- and timedemanding. It also shifts the gene landscape, thus complicating the interpretation and comparison of results. To overcome this issue, we have developed two approaches of transfer learning that allow for extending SOM space with new samples, meanwhile preserving its intrinsic structure. The extension SOM (exSOM) approach is based on adding secondary data to the existing SOM space by “meta-gene adaptation”, while supervised SOM portrayal (supSOM) adds support vector machine regression model on top of the original SOM algorithm to “predict” the portrait of a new sample. Both methods have been shown to accurately combine existing and new data. With simulated data, exSOM outperforms supSOM for accuracy, while supSOM significantly reduces the computing time and outperforms exSOM for this parameter. Analysis of real datasets demonstrated the validity of the projection methods with independent datasets mapped on existing SOM space. Moreover, both methods well handle the projection of samples with new characteristics that were not present in training datasets.

Aims An increasing number of children and adolescents worldwide suffer from inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC). The present work aims to investigate the incidence, prevalence and future trends of IBD in children and adolescents in Saxony, Germany. Methods The Saxon Pediatric IBD Registry collected data on patients up to 15 years of age from all 31 pediatric hospitals and pediatric gastroenterologists in Saxony over a 15-year period (2000–2014). In 2019, an independent survey estimated a registry completeness of 95.7%. Age-standardized incidence rates (ASR) per 100,000 person-years (PY) and prevalence per 100,000 children and adolescents were calculated. Evaluation was also been performed in sex and age subgroups. Joinpoint and Poisson regression were used for trend analyses and projections. Results 532 patients with confirmed IBD during 2000–2014 were included in the epidemiological evaluation. 63.5% (n = 338) patients had CD, 33.1% (n = 176) had UC and 3.4% (n = 18) had unclassified IBD (IBD-U). The 15-year IBD prevalence was 111.8 [95%-CI: 102.3–121.3] per 100,000. The incidence ASR of IBD per 100,000 PY over the whole observation period was 7.5 [6.9–8.1]. ASR for the subtypes were 4.8 [4.3–5.3] for CD, 2.5 [2.1–2.9] for UC and 0.3 [0.1–0.4] for IBD-U. The trend analysis of ASR using the joinpoint regression confirmed a significant increase for incidence of IBD as well as CD. For IBD, the ASR per 100,000 PY increased from 4.6 [2.8–6.3] in 2000 to 8.2 [7.5–13.6] in 2014; projected incidence rates for IBD in Germany are 12.9 [6.5–25.5] in the year 2025 and 14.9 [6.7–32.8] in 2030, respectively. Thus, the number of new IBD diagnoses in Germany would more than triple (325%) in 2030 compared to 2000. The increase is expected to be faster in CD than UC, and be more in males than in females. The expected number of newly diagnosed children with IBD in Germany is projected to rise to about 1,584 [1,512–1,655] in 2025, and to about 1,918 [1,807–2,29] in 2030. Conclusion The incidence of IBD in children and adolescents in Saxony increased at a similar rate as in other developed countries during the observation period. Given this trend, the health care system must provide adequate resources for the care of these young patients in the future.

Aim The incidence of inflammatory bowel disease (IBD) is increasing worldwide. The Saxon Pediatric IBD Registry was founded in 2000 to describe the epidemiology of pediatric IBD in Germany. The aim of this study was to determinate the completeness of this registry for children and adolescents younger than 15 years and to make this approach transparent. Results of this completeness update have broad implications for further scientific publications from the registry dataset. Method The capture–recapture method with two data sources was used to ascertain completeness. A second data source was collected in 2019 for the observation period 2008–2014 from all pediatricians, gastroenterologists, and internists working in practices in a predefined region in Saxony, Germany. Results A total of 23 patients with IBD were reported who fulfilled the inclusion criteria. One of them was not recorded in the registry. Therefore, the completeness of the registry was estimated at 95.7% (95% CI 90.2–100). Initial analysis of the Saxon Pediatric IBD Registry over the 15-year period 2000–2014 includes 532 patients, 312 (58.6%) male and 220 (41.4%) female. The distribution of single IBD diseases in the registry was as follows: Crohn’s disease 338 patients (63.5%), ulcerative colitis 176 patients (33.1%), and unclassified IBD 18 patients (3.4%). Evaluations by sex and by disease in age groups and by age at onset were tabulated. Conclusion This study demonstrates that the completeness level of the Saxon Pediatric IBD Registry is high (95.7%), and thus the epidemiological data of the registry are reliable.

Einleitung: Das Probiotikum E. coli Nissle 1917 (EcN) wird seit einigen Jahren erfolgreich in der Behandlung chronisch entzündlicher Darmerkrankungen angewendet, der zugrunde liegende Wirkmechanismus ist jedoch nur unzureichend geklärt. T-Zellen spielen in der intestinalen Immunhomöostase und der Pathogenese von CED eine zentrale Rolle. Ziel: Den Einfluss von EcN auf humane T-Zellen weitergehend zu charakterisieren. Methoden: CD3-stimulierte periphere und Lamina propria T-Zellen wurden mit verschiedenen Konzentrationen eines E. coli Nissle 1917 konditionierten Mediums (EcN-CM) oder aber hitzeinaktivierten E. coli Nissle 1917 (hi-EcN) kultiviert. Die Expression von zellzyklus- und apoptoseassoziierten Regulationsproteinen sowie DNA-Gehalt, Zellzykluskinetik, Apoptoserate und Zellexpansion wurden durchflusszytometrisch und im Western Blot bestimmt. Die Sekretion von Cytokinen wurde mit dem Cytometric Bead Assay bestimmt. Ergebnisse: EcN-CM, nicht aber hitzeinaktivierte E. coli Nissle 1917 hemmt die Zellzyklusprogression und die Expansion von stimulierten, humanen peripheren T-Zellen. Ursächlich hierfür ist eine verminderte Expression der Cykline A, B1, D2 und E mit einer konsekutiv verminderten Phosphorylierung des Retinoblastomaproteins. Periphere T-Zellen sezernieren unter EcN-CM vermindert IL-2, IFN-gamma und TNF-alpha, während die Sekretion des antiinflammatorischen IL-10 durch EcN-CM heraufreguliert wird. Im Gegensatz zur potenten Beeinflussung des Zellzyklus, wurde die Apoptose von PBT durch E. coli Nissle 1917 nicht moduliert. Während periphere T-Zellen durch EcN-CM in ihrer Zellzyklusprogression und Expansion gehemmt wurden, zeigte sich kein derartiger Effekt auf ortständige Lamina propria T-Lymphozyten. Diskussion: Bei chronisch entzündlichen Darmerkrankungen kommt es zu einer Rekrutierung und Aktivierung von peripheren T-Zellen in die intestinale Mukosa. Durch die differenzielle Beeinflussung des Immunsystems, bei der aktivierte periphere T-Zellen inhibiert, die ortsständigen T-Zellen jedoch in ihrer Funktion nicht gestört werden, könnte E. coli Nissle 1917 dazu beitragen, die mukosale Entzündungsreaktion zu limitieren, während die intestinale Immunhomöostase gewahrt bleibt. Als wirksames Agens kommen kleine, hitzestabile bakterielle Produkte wie Lipopolysaccharide, bakterielle Lipoproteine, CPG-DNA, Lipoteichonsäuren und Peptidoglykane in Frage. Die Ergebnisse der vorliegenden Arbeit liefern weitere Hinweise, dass Probiotika einen breiten Einfluss auf das humane Immunsystem haben und decken zugrundeliegende Mechanismen auf. / Introduction: Although probiotic Escherichia coli strain Nissle 1917 (EcN) has been proven to be efficacious for the treatment of inflammatory bowel diseases, the underlying mechanisms of action still remain elusive. T cells play a major role in the pathogenesis of inflammatory bowel disease. Aims: To analyze the effects of E. coli Nissle 1917 on cell cycling and apoptosis of peripheral blood and lamina propria T cells. Methods: Anti-CD3-stimulated peripheral or lamina propria T cells were treated with E. coli Nissle 1917-conditioned medium (EcN-CM) or heat-inactivated E. coli Nissle 1917. Expression of cell cycle or apoptosis related proteins was determined by immunoblotting, DNA content, cell cycle kinetics, cell expansion and apoptosis were measured by flow cytometry. Cytokine levels in culture supernatants were assessed by cytometrc bead array. Results: EcN-CM but not heat-inactivated EcN inhibits cell cycling and expansion of peripheral T cells. EcN-CM decreases expression of Cyclin A, B1, D2 and E and thus reduces phosphorylation of retinoblastomaprotein in CD3-stimulated peripheral T cells. Further, secretion of proinflammatory cytokines IL-2, IFN-gamma and TNF-alpha is reduced while antiinflammatory IL-10 is increased under treatment with EcN-CM. In contrast to peripheral T cells, expansion and cell cycle progression of lamina propria T cells was not affected by EcN-CM. Apoptosis of was not modulated by EcN-CM. Discussion: The differential reaction of circulating and tissue-bound T cells towards E. coli Nissle 1917 may explain the beneficial effect of EcN in intestinal inflammation. EcN may downregulate the expansion of newly recruited T cells into the mucosa and thus limit intestinal inflammation, while already activated tissue-bound T cells may eliminate deleterious antigens in order to maintain immunological homeostasis. Possible agents, for which immunomodulatory effects are known, include heat-stable bacterial products like lipopolysaccharids, bacterial lipoproteins or bacterial DNA-motifs.

A doença Inflamatória Intestinal (DII) é uma desordem caracterizada pela inflamação crônica do trato gastrointestinal. Os dois principais tipos de DII são a Retocolite Ulcerativa (RCU) e a Doença de Crohn (DC) e ambas cursam com importantes alterações no estado nutricional (EN). O objetivo deste estudo foi identificar as diferenças na composição corporal entre pacientes com DC, RCU e indivíduos saudáveis, além de comparar o estado nutricional dos três grupos de pacientes, ajustando para fatores que podem interferir no EN, como o uso atual de corticosteróides, a atividade física, a atividade de doença, a idade e o sexo. Foi realizado um estudo transversal que incluiu 101 pacientes com DII (50 com DC e 51 com RCU) e 35 indivíduos saudáveis, selecionados no Ambulatório do Hospital Universitário Pedro Ernesto (HUPE) da Universidade do Estado do Rio de Janeiro (UERJ). Foram colhidas informações sócio-demográficas e pessoais, tais como: prática de atividade física, tabagismo, doenças pregressas e procedimentos cirúrgicos prévios. Outras informações necessárias à pesquisa foram coletadas em prontuário médico. A avaliação antropométrica foi realizada por meio das seguintes medidas: peso corporal; altura; circunferências do braço, da cintura (CC) e do quadril; dobras cutâneas do tríceps, subescápula, supra-ilíaca e da coxa; e circunferência muscular do braço (CMB). A análise da composição corporal foi realizada por meio da bioimpedância elétrica (BIA), utilizando-se o aparelho Biodynamics modelo 450. As variáveis laboratoriais analisadas foram: glicose, hemograma completo, perfil lipídico, proteínas totais, albumina, globulina, velocidade de hemossedimentação e proteína C reativa. O peso, o índice de massa corporal, a CC e o percentual de gordura corporal calculado a partir da aferição das dobras cutâneas, foram menores nos pacientes com DC, quando comparados aos indivíduos saudáveis e/ou aos pacientes com RCU. A CMB foi menor nos pacientes com DC e RCU quando comparados aos indivíduos saudáveis, porém sem apresentar diferenças entre os dois grupos de pacientes. Por BIA, verificou-se que os pacientes com DC apresentaram valores de massa magra, massa celular corpórea, massa extracelular, água corporal total e água extracelular menores quando comparados aos indivíduos saudáveis. Os níveis séricos de colesterol total, proteínas totais e albumina, e a contagem total de hemácias foram menores nos indivíduos com DC quando comparados aos indivíduos do grupo controle e/ou aos indivíduos do grupo da RCU. Os pacientes com RCU exibem composição corporal semelhante à da população saudável. Em contraposição, os pacientes com DC apresentam EN amplamente comprometido com depleção de gordura corporal e massa magra em relação aos demais indivíduos / Inflammatory Bowel Disease (IBD) is a disorder characterized by diffuse inflammation of the gastrointestinal tract. The two main types of IBD are ulcerative colitis (UC) and Crohn's disease (CD), both coursing with important changes in nutritional status (NS). The objective of this study was to identify differences in body composition between patients with CD, UC, and healthy subjects and to compare the NS of these three groups of patients, adjusting for factors that can interfere in NS such as current use of corticosteroids, physical activity, disease activity, age and sex. It was conducted a cross-sectional study which included 101 patients with IBD (50 with CD and 51 with UC) and 35 healthy subjects, selected at the Ambulatory of Pedro Ernesto University Hospital (HUPE) of the Rio de Janeiro State University (UERJ). Socio-demographic and personal information such as physical activity, smoking, prior diseases and previous surgical procedures were collected. Other necessary information for the research were collected from medical records. The anthropometric evaluation was carried out through the following measures: body weight; height; mid-arm, waist and hip circumferences; skinfold thickness of the triceps, subscapular, suprailiac, and thigh; and mid-arm muscle circumference (MAMC). The body composition analysis was performed by bioelectrical impedance (BIA) using the equipment Biodynamics model 450. The laboratory variables analyzed, included: glucose, complete blood count, lipid profile, total protein, albumin, globulin, erythrocyte sedimentation rate, and C-reactive protein. Weight, body mass index, waist circumference, and percentage body fat calculated from skinfold measurements were lower in CD patients compared to healthy subjects and/or the patients with UC. The MAMC was lower in patients with CD and UC compared to healthy subjects, but without showing differences between the two groups of patients. Through BIA, it was found that CD patients had values of lean body mass, body cell mass, extracellular mass, total body water, and extracellular water smaller when compared to healthy subjects. Seric levels of total cholesterol, total protein, and albumin, as well as red blood cell count and relative count of lymphocytes were lower in the individuals with CD than the individuals of the control group and/or the patients with UC. Patients with UC exhibit body composition similar to that of the healthy population. In contrast, CD patients have widely NS committed with depletion of body fat and lean mass in relation to other individuals.